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Regenerative medicine aspires to reduce reliance on or overcome limitations associated with donor tissue-
mediated repair. Structural bone allografts are commonly used in orthopedic surgery, with a high percentage of
graft failure due to poor tissue integration. This problem is aggravated among elderly, those suffering from
metabolic conditions, or those undergoing cancer therapies that compromise graft healing. Toward this end, we
developed a synthetic graft named FlexBone, in which nanocrystalline hydroxyapatite (50wt%) was structurally
integrated with crosslinked poly(hydroxyethyl methacrylate) hydrogel, which provides dimensional stability
and elasticity. It recapitulates the essential role of nanocrystalline hydroxyapatite in defining the osteo-
conductivity and biochemical microenvironment of bone because of its affinity for biomolecules. Here, we
demonstrate that FlexBone effectively absorbed endogenously secreted signaling molecules associated with the
inflammation/graft healing cascade upon being press-fit into a 5-mm rat femoral segmental defect. Further, when
preabsorbedwith a single dose of 400 ng recombinant human (rh) bonemorphogenetic protein-2/7 heterodimer, it
enabled the functional repair of the critical-sized defect by 8–12 weeks. FlexBone was stably encapsulated by the
bridging bony callus and the FlexBone–callus interface was continuously remodeled. In summary, FlexBone
combines the dimensional stability and osteoconductivity of structural bone allografts with desirable surgical
compressibility and acquired osteoinductivity in an easy-to-fabricate and scalable synthetic biomaterial.
Introduction
Synthetic scaffolds designed to assist tissue repairshould exhibit useful surgical handling characteristics, a
biochemical microenvironment promoting proper cellular
response and tissue integration, and structural/chemical
properties ensuring long-term stability and safety. Synthetic
bone substitutes currently in clinical use (e.g., brittle ceram-
ics, weak polymer gel foams) rarely possess essential bone-
like structural and biochemical properties. In addition, they
often lack desirable physical properties that would facilitate
convenient surgical insertion and stable graft fixation and/or
they generate immunogenic/inflammatory degradation
products in vivo. Although new and exciting biomaterial
scaffolds incorporating sophisticated chemical and engi-
neering designs have been recently reported in literature,
they continue to present major hurdles, slowing their bench-
to-bedside translation.1
We believe that the sophisticated functional requirements
of a viable synthetic bone graft are not synonymous with
complicated materials designs. Instead, we propose that the
recapitulation of the multifaceted roles of nanocrystalline
hydroxyapatite (nHA), the key mineral component of bone,
as part of a strategy for the design of a synthetic scaffold will
lead to a successful bone graft substitute. Toward this end,
we developed FlexBone, a structural composite with up to
50wt% nHA structurally integrated within a hydroxylated
crosslinked carbon network.2 Despite its high mineral con-
tent, this structural composite can withstand repetitive
functional-compressive loads with excellent shape recovery
under physiological conditions.2 As a result of the high
surface area of the nHA component and its intrinsic affinity
for proteins and small molecule therapeutics,3,4 FlexBone is
also a suitable vehicle for delivering growth factors and an-
tibiotics in a sustained and localized manner in vitro (Sup-
plementary Fig. S1; Supplementary Data are available online
at www.liebertonline.com/ten).5 Further, FlexBone can be
predrilled with interconnecting channels to enable the mi-
gration of endogenous progenitor cells upon implantation.
Combined with its ease of preparation in large scale, safe
storage under ambient conditions, and the ability to be
supplemented with osteogenic protein therapeutics at the
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time of use, FlexBone has the potential to be an ‘‘off-the-
shelf’’ synthetic bone substitute for orthopedic applications.
In this study, we test the hypothesis that the elasticity, os-
teoconductivity, and dimensional stability exhibited by
FlexBone, combined with its osteoinductivity acquired from
preabsorbed recombinant human bone morphogenetic pro-
tein-2/7 heterodimer (rhBMP-2/7), makes it an effective
scaffold in enabling the functional repair of critical femoral
defects in rats.
As will be described, we utilized a 5-mm rat femoral seg-
mental defect model6 to evaluate the efficacy of FlexBone
comprising two mineral compositions, 50wt% nHA (FB-50),
or 25wt% nHA plus 25wt% tricalcium phosphate (TCP) (FB-
25-25). In addition, we also delivered the heterodimer BMP-2/
7 via FlexBone to facilitate the repair. BMP-2 and BMP-7 are
both Food and Drug Administration-approved protein ther-
apeutics for promoting skeletal repair.7 BMP-2 plays a critical
role in initiating fracture healing8 and is clinically used for
tibial fractures and spinal fusions. BMP-7 may play a larger
role in the later stages of bony repair9–11 and is routinely used
for spinal fusions and nonunions. It has been also used in
revision surgeries following inadequate repairs by BMP-2
treatment. BMP-2/7 heterodimer was shown to be a more
potent osteogenic factor than either homodimer in vitro12 and
can be used at a lower effective concentration.13 In this study,
we use the rhBMP-2/7 heterodimer to augment the os-
teointegration and graft healing of FlexBone.
Methods
Graft preparation
FlexBone with two mineral compositions, 50wt% nHA
(FB-50) or 25wt% nHA-25wt% TCP (FB-25-25), were pre-
pared to examine the potential impact of the faster dissolu-
tion of TCP14 on graft remodeling. FB-50 and FB-25-25 were
prepared as previously described.2 Briefly, freshly distilled
2-(hydoxyethl methacrylate) (HEMA) was mixed with ethyl-
ene glycol dimethacrylate (EGDMA) along with ethylene
glycol (EG), water, and aqueous radical initiators ammonium
persulfate (I-1, 480mg/mL) and sodium metasulfite (I-2,
180mg/mL) at a volume ratio of HEMA:EGDMA:EG:I-1:I-2
of 100:2:35:20:5:5. Nanocrystalline HA powder was then ad-
ded to the hydrogel mixture, thoroughly mixed, and allowed
to polymerize in rigid acrylic tubing of an inner diameter of
3.2mm (United States Plastic Corp.; tubes were washed with
absolute ethanol to remove radical inhibitors and air-dried
prior to use). The retrieved cylindrical FlexBone was cut into
segments of *5.5mm in length and drilled with two inter-
secting orthogonal drill holes (a longitudinal channel,
1.19mm in diameter, and an orthogonal channel, 0.79mm in
diameter, as illustrated in Fig. 1A) to allow bone marrow ac-
cess upon implantation. FlexBone was then thoroughly
equilibrated in MilliQ water to remove residual radical initi-
ators, unreacted monomers, ethylene glycol, and debris from
the drilling. After being sterilized with 70% ethanol, FlexBone
was re-equilibrated with sterile water and dried for storage.
Prior to surgical implantation, FlexBone was hydrated with
saline for*0.5 h (Supplementary Fig. S2) before an additional
8 mL saline or reconstituted rhBMP-2/7 solution (R&D Sys-
tems) was uniformly applied to give a final loading dose of
0 or 400 ng rhBMP-2/7 per graft.
Study design and surgical procedure
A 5-mm rat femoral segmental defect model6 (Fig. 1B) was
chosen to evaluate FlexBone-mediated skeletal repair as a
function of mineral composition and osteogenic growth
factor delivery. Four groups of FlexBone grafts (FB-50 and
FB-25-25, with or without 400 ng rhBMP-2/7) were press-fit
in 5-mm rat femoral defects, and the osteointegration of the
grafts were examined over time. A no-graft control group
was used to ensure the nonhealing nature of the 5-mm defect
without graft treatment. The rats were euthanized at 4 days,
2, 4, 6, 8, and 12 weeks for histological examination. In a
FIG. 1. Graft design (A), surgical procedure (B), and radiographic follow-ups (C). The femoral segmental defect was sur-
gically created by (i) securing a radiolucent polyetheretherketone (PEEK) plate fixator to the exposed femur (the periosteum
was circumferentially removed from the femur to which the PEEK plate was attached with bicortical screws); (ii, iii) generating
5-mmmiddiaphyseal defect under the plate fixator with an oscillating Hall sawwith parallel blades; and (iv) press-fitting a 5.5-
mm long FlexBone (with or without 400 ng BMP-2/7) into the defect. Radiographic follow-ups confirmed the alignment and
stability of the press-fit graft and the formation of a healing callus over 12 weeks. FB-50, FlexBone with 50wt% nanocrystalline
hydroxyapatite; FB-25-25, FlexBone with 25wt% nanocrystalline hydroxyapatite plus 25wt% tricalcium phosphate; BMP-2/7,
bone morphogenetic protein-2/7 heterodimer. Color images available online at www.liebertonline.com/ten.
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subset of 8- and 12-week rats, fresh frozen explanted femurs
were evaluated by microcomputed tomography (microCT)
and then tested to failure in torsion. To assess the role of
the nHA in retaining endogenous proteins on FlexBone
(see Detection for endogenous proteins absorbed on FlexBone
section), additional FB-50 grafts and unmineralized poly
(2-hydoxyethyl methacrylate) (pHEMA) control grafts were
press-fit into 5-mm defects and retrieved at 0.5 h, 1 day, 2
days, 4 days, and 1 week for immunohistological analysis. A
total of 160 defects were generated: 5 groups (FB-50 alone þ
FB-25-25 alone þ FB-50 with BMP þ FB25-25 with BMP þ 1
no-graft control)[6 time points3 (N¼ 3, histology) þ 2
time points5 (N¼ 5, MicroCT and torsion test)] þ 2 groups
(FB-50 alone þ unmineralized pHEMA control)5 time
points2 (N¼ 2, detection of endogenous proteins)¼ 160
defects. Finally, four intact femurs were collected for torsion
from healthy unoperated rats that were of the same age as
the rats receiving the grafts for 12 weeks.
All animal procedures were approved by the University
of Massachusetts Medical School Animal Care and Use
Committee. Briefly, sedated male Charles River SASCO-SD
rats (289–300 g) were maintained by 2% isoflurane–oxygen
throughout the surgery. The shaft of a femur was exposed
by a combination of sharp and blunt dissections and the
periosteum of the exposed femur was circumferentially
removed to emulate a challenging clinical scenario where
this important source of progenitor cells and signaling
molecules is lost. A radiolucent, weight-bearing poly-
etheretherketone (PEEK) internal fixation plate was secured
to the exposed femur with four bicortical screws into pre-
drilled holes. A 5-mm middiaphyseal defect was then cre-
ated using an oscillating Hall saw with parallel blades
(Fig. 1B). The defect site was thoroughly irrigated with sa-
line to remove bone debris and residue of detached peri-
osteum before it was press-fit with a FlexBone graft with or
without 400 ng rhBMP-2/7. The wounds were closed with
sutures and the rats were given cefazolin (20mg/kg) and
bupenorphine (0.08mg/kg) injections subcutaneously over
the next 2 days. Rats were radiographed post-op to ensure
proper graft positioning, and every 2 weeks thereafter to
monitor the mineralized callus formation over time. On
dates of scheduled explant retrieval, rats were sacrificed by
isoflurane and cervical dislocation. The repaired femur,
with the PEEK plate fixator intact, was carefully separated
from the adjacent hip and knee joints by an oscillating saw.
Histology and microscopy
To evaluate cellularity, new bone formation, remodeling,
and vascularization of the FlexBone over time, histochemi-
cal and immunohistochemical staining of the explants for
hematoxylin and eosin, osteogenic differentiation marker
alkaline phosphatase (ALP), osteoclast lineage marker tar-
trate-resistant acid phosphatase (TRAP), and chondrocytes
(by toluidine blue) was performed on 6-mm paraffin sections.
All explanted femurs were fixed in a periodate–lysine–
paraformaldehyde fixative15 at 48C for 2 days and decalcified
in 18% ethylenediaminetetraacetic acid (0.1M Tris, pH 7.0) at
48C for 4 weeks before they were bisected longitudinally for
paraffin embedment and sectioning. Polarized light micros-
copy was used to assess the orientation of collagen fibrils and
thus the maturity of new bone formation.
Detection of endogenous proteins absorbed
on FlexBone
FB-50 grafts and unmineralized pHEMA controls were
press-fit into the 5-mm critical-sized rat femoral defects in a
subset of experiments. The grafts were harvested and fixed at
0.5 h, 1 day, 2 days, 4 days, and 1 week, during which the
inflammatory/graft healing cascadewas initiated. Antibodies
for transforming growth factor b (TGFb) (detects precursor
and mature TGFb1, 2, and 3 isoforms; Santa Cruz), tumor
necrosis factor a (Novus Biologicals), interleukin-1b (Santa
Cruz), vascular endothelial growth factor (Santa Cruz),
receptor activator for nuclear factor kappa B ligand (RANKL)
(Abcam), BMP-2 (Novus Biologicals), BMP-7 (Abcam), and
stromal cell-derived factor (SDF)-1 (Santa Cruz) were used to
detect the endogenous proteins absorbed on FB-50 and
pHEMA at each time point. Unimplanted FB-50 were stained
for the same panel of antibodies and immunoglobulin G iso-
type (rabbit or mouse immunoglobulin G) control stains were
performed on all FB-50 explants retrieved at various time
points (Supplementary Information; Supplementary Fig. S4).
For the TGFb detection, positive control stain was performed
on a FB-50 graft loaded with 10 ng rhTGFb1 (R&D Systems),
and negative control stain using the blocking peptide (Santa
Cruz) along with the primary antibody was also carried out.
The immunohistochemical detection was performed on par-
affin-embedded sections as described above.
MicroCT and biomechanical tests
Fresh-frozen explants were scanned on a cone-beam eX-
plore Locus SP microCT system. The effective voxel size of
the reconstructed images was 181818 mm3. Images were
globally thresholded and analyzed to measure callus volume
and bone mineral content. Both ends of the same explants
were then potted in aluminum pots with molten bismuth
and mounted in a custom minitorsion tester. PEEK fixators
were carefully bisected using a high-speed burr under irri-
gation before the explants were loaded to failure (0.58/s), to
determine failure torque and energy to failure.
Statistical analyses
The Wilcoxon–Mann–Whitney ranked-sum test was used
to make all statistical comparisons and p-values <0.05 were
considered significant. All analyses were performed using
STATA (version 9.0) software.
Results
Partial healing of femoral critical defects by FlexBone
in the absence of exogenous growth factors
Elastomeric FlexBone grafts of either mineral composition,
predrilled with two intersecting orthogonal channels for
marrow penetrations (Fig. 1A), were readily press-fit into the
5-mm defects with excellent alignment to adjacent bones
(Fig. 1B). Radiographic monitoring of the graft healing by X-
ray (Fig. 1C) showed that the grafts remained stably posi-
tioned throughout the study, with calcified callus partially or
completely bridging over the defect by 12 weeks.
Histological analyses and polarized light microscopy
(Fig. 2) revealed that the osteoconductivity of FlexBone fa-
cilitated healing in the absence of exogenous osteogenic
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growth factors. Bone marrow penetration throughout the
orthogonal drill holes of the graft (FB-50), the emergence of
an external callus, and the formation of an internal/medul-
lary callus (within the graft drill hole and adjacent medullary
cavity; Fig. 2A) were evident at 4 days post-op (Fig. 2B). By 2
weeks, the external callus bridging over the defect was par-
tially mineralized, with ossification extending from the
graft–cortical bone interfaces toward the center of the callus.
Cartilage, stained purple by toluidine blue (Supplementary
Fig. S3), was prominently present at the mineralizing ends of
FIG. 2. Cartoon depiction (A), histological analyses (B) of the callus formation surrounding a femoral segmental defect fit
with FB-50 without recombinant human (rh) BMP-2/7, and immunohistological detection (C) of endogenous proteins ab-
sorbed on FB-50. Longitudinal sections of the explants obtained at various time points were stained for H&E, ALP (blue), and
TRAP (red) to assess the cellularity and tissue types and to monitor osteoblastic and osteoclastic activities within the healing
callus. Polarized light microscopy was used to assess collagen fibril orientation within the callus. Panel C selectively shows
the absorption of endogenous TGFb (see Supplementary Fig. S4 for a panel of additional proteins) on FB-50 within 1 week of
implantation in rat femoral defects. Negative control stains of the 2-day FB-50 explant using TGFb blocking peptide and
rabbit IgG isotype control, respectively, are selectively shown. Endogenous TGFb detected on pHEMA retrieved on day 2 is
representatively shown (see Supplementary Fig. S4 for other time points). Scale bars¼ 200mm. H&E, hematoxylin and eosin;
ALP, alkaline phosphatase; TRAP, tartrate-resistant acid phosphatase; TGFb, transforming growth factor b; pHEMA, poly
(2-hydoxyethyl methacrylate).
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the external callus, underscoring the endochondral ossifica-
tion mechanism. By 6 weeks, both the external and internal
calluses were significantly remodeled and matured as evi-
denced by the recanalization16 and the formation of oriented
collagen fibrils revealed by polarized microscopy.17 Al-
though even greater orientation of collagen fibrils within the
external callus was observed beyond 6 weeks, bridging of the
defect by fully mineralized callus was not achieved by 12
weeks without rhBMP-2/7.
Remodeling activity (indicated by positive ALP and TRAP
stains) was detected within internal, external, and medullary
calluses throughout the 12-week study. A line of osteoclastic
activity (red TRAP stain) was typically observed at the
FlexBone–callus interface, followed by a distinct line of os-
teoblastic activity (blue ALP stain), suggesting coordinated
remodeling and osteointegration of FlexBone. Quantification
of the numbers of TRAP-positive cell nuclei and ALP-
positive cell nuclei at the graft–callus interface over time
(Supplementary Table S1) revealed persisting active graft
remodeling activities by 6 weeks as evidenced by the in-
creased osteoclastic activities compared with those detected
at 2 weeks. Intense TRAP and ALP stains were still detected
at the FlexBone–callus interface at 12 weeks, suggesting that
graft remodeling would continue over an extended period of
time. Histological analysis of the FB-25-25 graft healing over
time revealed similar observations.
In a subset of experiments (Supplementary Fig. S4), we
showed that FlexBone effectively absorbed a number of en-
dogenously secreted factors (TGFb, interleukin-1b, tumor
necrosis factor a, vascular endothelial growth factor,
RANKL, BMP-2, BMP-7, and SDF-1) associated with the
initiation of the inflammation18,19/graft healing cascade20
and the recruitment of progenitor cells.21,22 The majority of
these factors were initially (0.5 h after implantation) detected
on the surface of the graft where progenitor cells were re-
cruited to, and then the secreted molecules quickly pene-
trated throughout the three-dimensional network and were
effectively retained by the nHA component (Fig. 2C). In
contrast, the unmineralized pHEMA controls were not able
to attract and retain these endogenously secreted molecules
within its three-dimensional network.
Expedited healing of femoral critical defects
by FlexBone in the presence of rhBMP-2/7
Acceleration of graft healing by delivery of rhBMP-2/7
using FlexBone was examined with each mineral composi-
tion. The capacity of FlexBone to locally deliver exogenous
rhBMP-2/7 enhanced the graft osteoinductivity and led to
expedited repair of the critical-sized femoral defects by 8
weeks (Fig. 3). When press-fit with FlexBone (FB-50) con-
taining 400 ng rhBMP-2/7, the defect was completely
bridged by maturing and recanalizing internal and external
bony calluses at 6 weeks. By 8 weeks, the collagen fibrils in
the healing calluses exhibited excellent alignment with little
change observed beyond that point. FB-25-25 supplemented
with 400 ng rhBMP-2/7 enabled the formation of bridging
bony calluses in a similar fashion. The accelerated active
graft remodeling in the presence of rhBMP-2/7 was evi-
denced by >50% higher counts of TRAP-positive cell nuclei
at 2 weeks post-op, and a more rapid drop of the number by
6 weeks when compared with those observed for the group
without BMP-2/7 treatment (Supplementary Table S1).
Quantitative assessment of the repair of femoral
critical defects by FlexBone as a function
of mineral composition and rhBMP-2/7 treatment
Quantitative assessment of the healing callus formation by
microCT (Fig. 4A) and torsion testing (Fig. 4B) indicated
successful functional repair of the critical-sized femoral de-
fects by 12 weeks using FlexBone augmented with 400 ng
rhBMP-2/7. Three-dimensional reconstruction of the mi-
FIG. 3. Histological analyses of the callus formation surrounding a femoral segmental defect fit with FB-50 with
recombinant human (rh) BMP-2/7 (400 ng). Longitudinal sections of the explants obtained at various time points were
stained for H&E, ALP (blue), and TRAP (red) to assess the cellularity and tissue types and to monitor osteoblastic and
osteoclastic activities within the healing callus. Polarized light microscopy was used to assess collagen fibril orientation
within the callus. Scale bars¼ 200 mm.
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FIG. 4. Microcomputed tomography analyses (A) and torsion tests (B) of 12-week explants as a function of graft min-
eral composition and BMP-2/7 treatment. Effective voxel size of 181818 mm3 was applied to the reconstructed three-
dimensional isosurface images and the two-dimensional color maps of the center slice of the explants (red representing a higher
degree of mineralization). Graphed data are presented as boxplots, where red dots indicate median values and blue dots represent
sample outliers. Note that FB explants without BMP-2/7 treatment did not fail during the torsion test (likely due to the lack of a
fully bridging stiff bony callus and the elasticity of underlying FlexBone). #The values reported represent the torque and energy at
which the testing was stopped. *p< 0.05 is considered significant. Color images available online at www.liebertonline.com/ten.
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croCT scans revealed robust mineralized external callus
completely bridging over the FlexBone-filled defects when
supplemented with rhBMP-2/7. Two-dimensional color
maps of the center cross-sections confirmed that the mid-
point of these grafts was fully encapsulated with mature and
recanalized external and internal mineralized calluses. In
contrast, defects filled by FlexBone of either mineral com-
position without rhBMP-2/7 treatment were only partially
bridged by mineralized calluses. With the treatment of a
single dose of 400 ng BMP-2/7, bone volume fractions and
bone mineral contents of the 12-week explants increased by
>100%. From 8 to 12 weeks post-op, defects treated with FB-
50 and rhBMP-2/7 showed little increase in bone mineral
content (Supplementary Fig. S5B) but a 20% increase in bone
volume fraction (Supplementary Fig. S5A), suggesting con-
tinued remodeling of the bony callus beyond 8 weeks.
The remarkable healing achieved by a combination of
osteogenesis and osteoconduction in the growth factor–
treated group translated into the restoration of torsional
strength of the femoral defects. The maximum torque and
energy to failure values of the explants in the rhBMP-2/7–
treated group approximate those of intact femurs (Fig. 4B),23
or the femoral defects repaired by gene therapy,20,24 and
surpass those accomplished by allograft-mediated repair.25
Despite an upward trend over time, the observed difference
in failure torque or failure energy between the 8- and 12-
week explants was statistically insignificant (Supplementary
Fig. S5C, D), suggesting that the bony callus formed at 8
weeks already possessed adequate strength.
Discussion
We have shown that FlexBone, a structural composite of
nHA and hydrophilic pHEMA hydrogel matrix, possessed
unique properties desired for the repair of critical-sized
femoral defects. The elasticity of FlexBone allowed for its
convenient and stable press-fitting into a critical-sized fem-
oral defect, which was stabilized by a weight-bearing fixa-
tion plate. Predrilled interconnected channels facilitated bone
marrow penetration and enabled the stabilization of the
defect via the formation of both internal and external cal-
luses. Effective recruitment of bone marrow progenitor cells
via the drill holes and the affinity of the nHA component for
endogenously secreted signals required for initiating the in-
flammation/graft healing cascade are likely contributors to
the partial repair enabled by FlexBone in the absence of any
exogenous osteogenic factor.
Further, we demonstrate that the local delivery of low-
dose rhBMP-2/7 via FlexBone (400 ng/graft) enabled expe-
dited functional repair of the critical defect by 8–12 weeks via
its acquired osteoinductivity. The biomechanical function of
the defect was restored to the level comparable to those
achieved by successful gene therapy, but without the com-
mon risks associated with the latter.20,24 This was likely due
to the robust host-to-host junction of the bridging bony cal-
lus, the increase in cross-sectional area (callus volume), and
the degree of mineralization of the new bone collar. The low
rhBMP-2/7 working dose accomplished in this study is 1–2
orders of magnitude lower than those utilized in the rhBMP-
2 therapy in treating similar defects,26,27 likely resulting from
a combination of higher potency of the heterodimer and
the ability of FlexBone to release it in a more sustained and
localized manner.5 This feature could be translated into
FlexBone-mediated delivery of protein therapeutics in a
more cost-effective and safer fashion (e.g., with less proteins
rapidly diffused away from the carrier), potentially benefit-
ing the clinical treatment of hard-to-heal bony lesions.
No significant difference in the functional outcome (based
on microCT and torsion data) of FlexBone-assisted repair of
critical femoral defects was observed by 12 weeks between
the two mineral compositions examined (FB-50 vs. FB-25-25).
To fully reveal the impact of the different dissolution rates of
TCP versus nHA on graft remodeling, detailed microstruc-
tural analyses of the healing callus over a longer period of
time would be necessary. The choice for mineral composition
will likely be dictated by the desired physical properties of
the scaffold for any given application. For instance, FB-25-25
has higher compressability than FB-50 under physiological
conditions, achieving 25% strain (as opposed to 10% for FB-
505) under 0.5MPa compressive load,2 making it easier to be
press-fit into a defect with limited accessibility. The stiffer
properties of the FB-50, on the other hand, could enable the
graft more tightly fit within an open defect.
The dimensional stability and biocompatibility of Flex-
Bone, along with the persistent remodeling observed at the
graft–callus interface, resemble some of the best features of
structural allografts.28 Patients receiving a successful struc-
tural allograft implantation would often live with the allo-
graft for life, with the graft being slowly remodeled over
time, generating little inflammatory degradation product.
Unlike the overwhelming numbers of biodegradable poly-
meric bone substitutes designed for tissue engineering ap-
plications,29 the crosslinked pHEMA hydrogel network in
FlexBone is not hydrolytically degradable by design. Vital
organs collected from the rats receiving FlexBone implants
for 12 weeks were pathologically indistinguishable from age-
matched control organs harvested from unoperated rats
(Supplementary Fig. S6). We argue that biodegradability is
not a functional requirement of viable synthetic bone grafts.
However, to further explore the clinical potential of Flex-
Bone, in vivo studies using large animal models and full
toxicological analyses for determining the longer-term re-
modeling pattern and safety (longer-term systemic effects) of
FlexBone need to be carried out.
In summary, FlexBone combines some of the best features
of structural allografts (osteoconductivity and dimensional
stability)29–31 with desirable surgical compressibility and
scalability of synthetic biomaterials. The ability of FlexBone
to locally deliver biological therapeutics in a significantly
reduced effective dose to enable expedited functional repair
of the critical defect opens the door to engineer the bio-
chemical properties of the graft21 based on individual needs.
More broadly, our work supports the notion that functional
sophistication of synthetic tissue grafts is not synonymous
with complicated chemical/engineering designs.1 We show
that by recapitulating the multifaceted roles that key extra-
cellular matrix components play in defining tissue-specific
microenvironment, easy-to-prepare biomaterials can be de-
signed to facilitate functional tissue repair.
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